NCT04377672View on ClinicalTrials.gov

Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2 (COVID-19)

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

May 28, 2020

Primary Completion Date

September 1, 2021

Study Completion Date

December 13, 2021

Conditions
SARS-CoV-2 Infection
Interventions
BIOLOGICAL

Anti-SARS-CoV-2 Human Convalescent Plasma

"1-2 unit (200-250 mL per unit) of plasma with anti-SARS-CoV-19 titers of ≥1:320.~The total volume (mL) infused will be based on weight (5 mL/kg) with a maximum volume of 500 mL."

Trial Locations (1)

21287

Johns Hopkins Hospitals, Baltimore

All Listed Sponsors
lead

Johns Hopkins University

OTHER

NCT04377672 - Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2 (COVID-19) | Biotech Hunter | Biotech Hunter